Tal Zaks's Israeli startup targets rare genetic diseases
"This type of gene editing should also allow for the treatment of diseases whose origin is not genetic or whose origin cannot ...
Why MRNA Stock Is Retreating
RNA vaccine developer Moderna (MRNA) is sinking 9% after Goldman Sachs downgraded the shares to Neutral from Buy. Why Goldman ...